At the SPD 2022 47th annual meeting, investigators share data on the treatment of ruxolitinib for this chronic autoimmune disease.
For adolescents, vitiligo (which occurs when pigment-producing cells die or stop functioning, resulting in skin depigmentation) can carry a heavy psychosocial burden. Investigators David Rosmarin, MD, Julien Seneschal, MD, PhD; and Pearl Grimes, MD et al shared the results of their study on the use of the cream formulation of the Janus kinase (JAK 1/JAK 2 inhibitor) ruxolitinib.
In 2 randomized, double-blind, vehicle-controlled, 52-week phase 3 studies in adults and adolescents who had vitiligo, ruxolitinib demonstrated considerable repigmentation. The Topical Ruxolitinib Evaluation in Vitiligo Study 1 and 2 (TruE-V1, TruE-V2) was conducted in North America and Europe, with patients 12 years and older diagnosed with nonsegmental vitiligo with depigmentation covering body area, including facial. Patients used ruxolitinib cream twice daily for 24 weeks, after which the patients could apply 1.5% of the cream through week 52.
Adverse events (AEs) in adolescents occurred in 12.9% of patients, while serious AEs occurred in only 1.4% of patients, with none considered related to treatment. Furthermore, efficacy results were similar to those in the adult population.
The results proved positive, with adolescent patients with nonsegmental vitiligo achieving substantial repigmentation with ruxolitinib cream vs vehicle at week 24, with a higher proportion of patients responding to the cream at week 52. Overall, ruxolitinib was well tolerated, with no severe adverse events considered related to treatment. Dermatologic practitioners should consider the positive outcomes of this study when setting up a treatment plan for their patients with vitiligo.
Reference
Rosmarin D, Seneschal J, Grimes P, et al. Efficacy and safety of ruxolitinib cream in adolescent patients with vitiligo: pooled analysis of the 52-week TRuE-V Phase 3 Studies. SPD 2022 47th Annual Meeting. Poster presentation. July 8, 2022. Indianapolis, Indiana.
Recognize & Refer: Hemangiomas in pediatrics
July 17th 2019Contemporary Pediatrics sits down exclusively with Sheila Fallon Friedlander, MD, a professor dermatology and pediatrics, to discuss the one key condition for which she believes community pediatricians should be especially aware-hemangiomas.
Worsening severity of AD in children associated with increased comorbidity onset risk
November 27th 2023Of patients in the atopic dermatitis (AD) cohort, 36.6% developed at least 1 comorbidity amid follow-up compared to 28.5% in the non-AD reference cohort, investigators of a Sweden, nationwide, population-based cohort study found.
IDP-126 topical gel approved by FDA to treat acne in patients 12 years and up
October 21st 2023The topical gel is the first and only FDA-approved triple-combination, fixed-dose topical treatment for acne, and is set to be available in the first quarter of 2024, according to Bausch Health Companies Inc.
A 13-year-old girl with well-demarcated rash on back and chest
October 19th 2023A healthy 13-year-old girl presented with a 1-month history of an asymptomatic, well-demarcated rash on her back and upper chest. The eruption consisted of discrete, dark brown papules that coalesced into large, flat-topped plaques with mild superficial scale and accentuation of skin markings. What's the diagnosis?
Tapinarof cream 1% reduces itch as early as 24 hours after application for pediatric AD
October 13th 2023A rapid reduction in pruritis as early as 24 hours after first application was announced as new positive data from a pair of identical, phase 3 studies of tapinarof cream 1% in children as young as 2 years and adults with atopic dermatitis (AD).